



**THE FOUNDATION
FOR SECURE
MARKETS**

#46027

DATE: NOVEMBER 20, 2019

SUBJECT: CELGENE CORPORATION – CONTRACT ADJUSTMENT
OPTION SYMBOLS: CELG/1CELG/2CELG
NEW SYMBOLS: BMY1/1BMY1/2BMY1
**FUTURES SYMBOLS: CELG1D/CELG3H/CELG4F/CELG1K/
CELG4M/CELG4T/CELG4W/CELG1L/CELG1I/CELG1J**
**NEW SYMBOLS: CELG2D/CELG6H/CELG6F/CELG2K/CELG6M/
CELG6T/CELG6W/CELG2L/CELG2I/CELG2J**
DATE: 11/21/19

Contract Adjustment

DATE: November 21, 2019

OPTION SYMBOLS: CELG changes to BMY1
1CELG changes to 1BMY1
2CELG changes to 2BMY1

STRIKE DIVISOR: 1

**CONTRACTS
MULTIPLIER:** 1

NEW MULTIPLIER: 100 (e.g., a premium of 1.50 yields \$150; a strike of 90.00 yields \$9,000.00)

**NEW DELIVERABLE
PER CONTRACT:** 1) 100 Bristol-Myers Squibb (BMY) Common Shares
2) 100 Contingent Value Rights (BMYRT)
3) \$5,000.00 Cash (\$50.00 x 100)

**SETTLEMENT
ALLOCATION:** BMY: 95%
BMYRT: 5%

CUSIP: BMY: 110122108
BMYRT: 110122157

THE SETTLEMENT ALLOCATION OF THE TOTAL STRIKE PRICE AMOUNT IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION (NSCC), AND IS NOT INTENDED TO BE USED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS.

PRICING

The underlying price for BMY1/1BMY1/2BMY1 will be determined as follows:

$$\text{BMY1/1BMY1/2BMY1} = \text{BMY} + \text{BMYRT} + 50.00$$

Futures Contract Adjustment

DATE: November 21, 2019

FUTURES SYMBOLS: CELG1D changes to CELG2D
CELG3H changes to CELG6H
CELG4F changes to CELG6F
CELG1K changes to CELG2K
CELG4M changes to CELG6M
CELG4T changes to CELG6T
CELG4W changes to CELG6W
CELG1L changes to CELG2L
CELG1I changes to CELG2I
CELG1J changes to CELG2J

NUMBER OF
CONTRACTS: No Change

MULTIPLIER 100 (e.g., a premium of 1.50 yields \$150)

NEW DELIVERABLE
PER CONTRACT: 1) 100 Bristol-Myers Squibb (BMY) Common Shares
2) 100 Contingent Value Rights (BMYRT)
3) \$5,000.00 Cash (\$50.00 x 100)

SETTLEMENT
ALLOCATION: BMY: 95%
BMYRT: 5%

CUSIP: BMY: 110122108
BMYRT: 110122157

THE SETTLEMENT ALLOCATION IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION (NSCC), AND IS NOT INTENDED TO BE USED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS.

PRICING

The underlying price for the CELG2D/CELG6H/CELG6F/CELG2K/CELG6M/CELG6T/CELG6W/CELG2L/CELG2I/CELG2J Futures contract deliverables, expressed in term of current market value, will be calculated as follows:

$$\text{CELG2D} = \text{BMY} + \text{BMYRT} + 50.00$$

Please note that the valuation would apply only to the CELG2D/CELG6H/CELG6F/CELG2K/CELG6M/CELG6T/CELG6W/CELG2L/CELG2I/CELG2J deliverable in terms of current market value of the deliverable securities. The resulting price would not be equivalent to the daily settlement price of a futures contract month, whose determination would include cost of money carrying charges, adjustment for dividends, and other factors.

BACKGROUND

On April 12, 2019, Shareholders of Celgene Corporation (CELG) voted concerning the proposed merger with Bristol-Myers Squibb (BMY). The merger was approved and consummated on November 20, 2019. As a result, each existing CELG Common Share will be converted into the right to receive 1.0 BMY Common Share, 1.0 Contingent Value Right (BMYRT) plus \$50.00 Cash.

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.